Literature DB >> 22410648

White matter hyperintensities predict amyloid increase in Alzheimer's disease.

Timo Grimmer1, Maximilian Faust, Florian Auer, Panagiotis Alexopoulos, Hans Förstl, Gjermund Henriksen, Robert Perneczky, Christian Sorg, Behrooz H Yousefi, Alexander Drzezga, Alexander Kurz.   

Abstract

Impaired amyloid clearance probably contributes to increased amyloid deposition in sporadic Alzheimer's disease (AD). Diminished perivascular drainage due to cerebral small-vessel disease (CSVD) has been proposed as a cause of reduced amyloid clearance. White matter hyperintensities (WMHs) are considered to reflect CSVD and can be measured using fluid-attenuated inversion recovery (FLAIR) magnetic resonance imaging (MRI). Amyloid deposition can be determined in vivo using Pittsburgh compound B ([11C]PiB) positron emission tomography (PET). We aimed to elucidate the association between WMH and the progression of amyloid deposition in patients with AD. Twenty-two patients with probable AD underwent FLAIR-MRI and [11C]PiB-PET examinations at baseline (BL) and after a mean follow-up (FU) interval of 28 months. The relationship between BL-WMH and the progression of cerebral amyloid between BL and FU was examined using a regions-of-interest (ROI) approach. The region-specific variability of this relationship was analyzed using a voxel-based method. The longitudinal analysis revealed a statistically significant association between the amount of BL-WMH and the progression of amyloid load between BL and FU (p = 0.006, adjusted R2 = 0.375, standardized coefficient β = 0.384). The association was particularly observed in parieto-occipital regions and tended to be closer in regions adjacent to the brain surface. According to our knowledge, this is the first in vivo study in human being supporting the hypothesis that impaired amyloid clearance along perivascular drainage pathways may contribute to β-amyloid deposition in sporadic AD. The extent of WMH might be a relevant factor to be assessed in antiamyloid drug trials.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22410648     DOI: 10.1016/j.neurobiolaging.2012.01.016

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  54 in total

1.  Interactive Associations of Vascular Risk and β-Amyloid Burden With Cognitive Decline in Clinically Normal Elderly Individuals: Findings From the Harvard Aging Brain Study.

Authors:  Jennifer S Rabin; Aaron P Schultz; Trey Hedden; Anand Viswanathan; Gad A Marshall; Emily Kilpatrick; Hannah Klein; Rachel F Buckley; Hyun-Sik Yang; Michael Properzi; Vaishnavi Rao; Dylan R Kirn; Kathryn V Papp; Dorene M Rentz; Keith A Johnson; Reisa A Sperling; Jasmeer P Chhatwal
Journal:  JAMA Neurol       Date:  2018-09-01       Impact factor: 18.302

2.  Reduced retention of Pittsburgh compound B in white matter lesions.

Authors:  Lidia Glodzik; Henry Rusinek; Jinyu Li; Cyrus Zhou; Wai Tsui; Lisa Mosconi; Yi Li; Ricardo Osorio; Schantel Williams; Catherine Randall; Nicole Spector; Pauline McHugh; John Murray; Elizabeth Pirraglia; Shankar Vallabhajolusa; Mony de Leon
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-10-21       Impact factor: 9.236

3.  Imaging Vascular Disease and Amyloid in the Aging Brain: Implications for Treatment.

Authors:  Sylvia Villeneuve; William J Jagust
Journal:  J Prev Alzheimers Dis       Date:  2015-03

4.  Greater progression of coronary artery calcification is associated with clinically relevant cognitive impairment in type 1 diabetes.

Authors:  Jingchuan Guo; Karen A Nunley; Tina Costacou; Rachel G Miller; Caterina Rosano; Daniel Edmundowicz; Trevor J Orchard
Journal:  Atherosclerosis       Date:  2018-11-08       Impact factor: 5.162

5.  A Clinicopathological Investigation of White Matter Hyperintensities and Alzheimer's Disease Neuropathology.

Authors:  Michael L Alosco; Michael A Sugarman; Lilah M Besser; Yorghos Tripodis; Brett Martin; Joseph N Palmisano; Neil W Kowall; Rhoda Au; Jesse Mez; Charles DeCarli; Thor D Stein; Ann C McKee; Ronald J Killiany; Robert A Stern
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

6.  Plasma antioxidants and brain glucose metabolism in elderly subjects with cognitive complaints.

Authors:  Agnese Picco; M Cristina Polidori; Michela Ferrara; Roberta Cecchetti; Dario Arnaldi; Mauro Baglioni; Silvia Morbelli; Patrizia Bastiani; Irene Bossert; Giuliana Fiorucci; Andrea Brugnolo; Massimo Eugenio Dottorini; Flavio Nobili; Patrizia Mecocci
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-12-03       Impact factor: 9.236

7.  White matter hyperintensities are associated with amyloid burden in APOE4 non-carriers.

Authors:  Young Noh; Sang Won Seo; Seun Jeon; Jong Min Lee; Jung-Hyun Kim; Geon Ha Kim; Hanna Cho; Cindy W Yoon; Hee Jin Kim; Byoung Seok Ye; Sung Tae Kim; Yearn Seong Choe; Kyung-Han Lee; Jae Seung Kim; Michael Ewers; Michael W Weiner; Jae-Hong Lee; David J Werring; Dae Ryong Kang; Chang Soo Kim; Duk L Na
Journal:  J Alzheimers Dis       Date:  2014       Impact factor: 4.472

8.  Reduced glucose uptake and Aβ in brain regions with hyperintensities in connected white matter.

Authors:  L Glodzik; A Kuceyeski; H Rusinek; W Tsui; L Mosconi; Y Li; R S Osorio; S Williams; C Randall; N Spector; P McHugh; J Murray; E Pirraglia; S Vallabhajosula; A Raj; M J de Leon
Journal:  Neuroimage       Date:  2014-07-04       Impact factor: 6.556

9.  Cognitive profile of amyloid burden and white matter hyperintensities in cognitively normal older adults.

Authors:  Trey Hedden; Elizabeth C Mormino; Rebecca E Amariglio; Alayna P Younger; Aaron P Schultz; J Alex Becker; Randy L Buckner; Keith A Johnson; Reisa A Sperling; Dorene M Rentz
Journal:  J Neurosci       Date:  2012-11-14       Impact factor: 6.167

Review 10.  What is normal in normal aging? Effects of aging, amyloid and Alzheimer's disease on the cerebral cortex and the hippocampus.

Authors:  Anders M Fjell; Linda McEvoy; Dominic Holland; Anders M Dale; Kristine B Walhovd
Journal:  Prog Neurobiol       Date:  2014-02-16       Impact factor: 11.685

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.